(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are FibroGen, AGBA Acquisition Limited, and Aesthetic Medical International Holdings Group Ltd..

Rank Financial Asset Price Change Updated (EST)
1 FibroGen (FGEN) 10.24 29.03% 2022-05-10 13:46:48
2 AGBA Acquisition Limited (AGBAW) 0.06 19.76% 2022-05-09 23:10:05
3 Aesthetic Medical International Holdings Group Ltd. (AIH) 1.47 18.55% 2022-05-09 23:46:15
4 FuboTV (FUBO) 3.40 16.84% 2022-05-10 14:12:27
5 Cronos Group (CRON) 3.24 14.52% 2022-05-10 13:37:46
6 Avadel Pharmaceuticals plc (AVDL) 4.38 11.45% 2022-05-10 09:12:05
7 argenx SE (ARGX) 299.92 11.25% 2022-05-10 14:56:44
8 Berkeley Lights (BLI) 4.92 10.56% 2022-05-10 13:11:07
9 Viking Therapeutics (VKTX) 2.47 10.27% 2022-05-10 14:01:01
10 Seattle Genetics (SGEN) 119.77 10.07% 2022-05-10 13:50:08

The three most active and biggest losers today are Alberton Acquisition Corporation, Artelo Biosciences, and Bellerophon Therapeutics.

Rank Financial Asset Price Change Updated (EST)
1 Alberton Acquisition Corporation (ALACW) 0.01 -55.56% 2022-05-10 01:12:05
2 Artelo Biosciences (ARTLW) 0.06 -28.81% 2022-05-10 07:20:05
3 Bellerophon Therapeutics (BLPH) 0.90 -24.14% 2022-05-10 13:14:13
4 American Virtual Cloud Technologies (AVCT) 0.41 -19.76% 2022-05-10 09:14:05
5 Adial Pharmaceuticals (ADILW) 0.32 -19.65% 2022-05-09 22:17:05
6 Axonics Modulation Technologies (AXNX) 39.50 -17.74% 2022-05-10 10:07:39
7 AlloVir (ALVR) 4.10 -17.51% 2022-05-10 02:07:20
8 BELLUS Health (BLU) 6.46 -16.32% 2022-05-10 13:15:14
9 Arvinas (ARVN) 38.54 -15.63% 2022-05-10 07:23:13
10 BridgeBio Pharma (BBIO) 5.66 -15.52% 2022-05-10 11:07:20

Most Active Winners today

1. FibroGen (FGEN) – 29.03%

FibroGen, Inc., is a biopharmaceutical firm that develops, commercializes, and markets therapeutics for serious unmet medical need. Roxadustat is an oral small-molecule inhibitor of hypoxia induce factor prolylhydroxylases. It’s currently in phase III clinical development. Phase II development is underway in China. Phase II/III is for myelodysplastic anemia. Pamrevlumab is a monoclonal human antibody that blocks the activity of connective tissues growth factor. It is currently in Phase III clinical trials for treatment of diabetes, idiopathic lung fibrosis and pancreatic cancer. There is also a Phase II trial to treat Duchenne muscular dysfunction. Astellas Pharma Inc., AstraZeneca AB and others have signed collaboration agreements. It was founded in 1993, and has its headquarters in San Francisco.

NASDAQ ended the session with FibroGen jumping 29.03% to $10.24 on Tuesday, after five successive sessions in a row of losses. NASDAQ jumped 1.65% to $11,815.23, after three consecutive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Volume

Today’s last reported volume for FibroGen is 1687860 which is 121.17% above its average volume of 763118.

FibroGen’s last close was $7.94, 73.64% below its 52-week high of $30.12.

FibroGen’s Sales

FibroGen’s sales growth is a negative 29.8% for the current quarter and a decline by 2.5% for the next. The company’s growth estimates for the current quarter is a negative 4.7% and positive 15.4% for the next.

FibroGen’s Revenue

Year-on-year quarterly revenue growth grew by 254.2%, now sitting on 283.76M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

FibroGen’s stock is considered to be overbought (>=80).

FibroGen’s Stock Yearly Top and Bottom Value

FibroGen’s stock is valued at $10.24 at 17:32 EST, way under its 52-week high of $30.12 and way above its 52-week low of $9.26.

FibroGen’s Moving Average

FibroGen’s worth is way below its 50-day moving average of $12.45 and way below its 200-day moving average of $12.75.

More news about FibroGen.

2. AGBA Acquisition Limited (AGBAW) – 19.76%

NASDAQ ended the session with AGBA Acquisition Limited rising 19.76% to $0.06 on Tuesday while NASDAQ jumped 1.65% to $11,815.23.

AGBA Acquisition Limited’s last close was $0.06, 14.41% under its 52-week high of $0.07.

AGBA Acquisition Limited’s Stock Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.06 at 17:32 EST, under its 52-week low of $0.06.

More news about AGBA Acquisition Limited.

3. Aesthetic Medical International Holdings Group Ltd. (AIH) – 18.55%

Aesthetic International Holdings Limited offers aesthetic medical services. The company offers aesthetic services such as liposuction, eye surgery and rhinoplasty. It also provides non-surgical treatments that are minimally invasive, energy-based, like laser, ultrasound and UV light. It also offers general medical and aesthetic services such as gynecology and internal medicine. There are 28 centers located in China, Hong Kong and Singapore. It was established in Shenzhen in China in 1997.

NASDAQ ended the session with Aesthetic Medical International Holdings Group Ltd. rising 18.55% to $1.47 on Tuesday while NASDAQ jumped 1.65% to $11,815.23.

Volume

Today’s last reported volume for Aesthetic Medical International Holdings Group Ltd. is 16819 which is 45.49% below its average volume of 30855.

Aesthetic Medical International Holdings Group Ltd.’s last close was $1.37, 87.81% under its 52-week high of $11.24.

Aesthetic Medical International Holdings Group Ltd.’s Sales

Aesthetic Medical International Holdings Group Ltd.’s sales growth is 1485.3% for the current quarter and 38.8% for the next.

Aesthetic Medical International Holdings Group Ltd.’s Revenue

Year-on-year quarterly revenue growth declined by 79.2%, now sitting on 1.08B for the twelve trailing months.

Aesthetic Medical International Holdings Group Ltd.’s Stock Yearly Top and Bottom Value

Aesthetic Medical International Holdings Group Ltd.’s stock is valued at $1.47 at 17:32 EST, way under its 52-week high of $11.24 and way higher than its 52-week low of $1.17.

Aesthetic Medical International Holdings Group Ltd.’s Moving Average

Aesthetic Medical International Holdings Group Ltd.’s worth is way under its 50-day moving average of $1.87 and way under its 200-day moving average of $3.27.

More news about Aesthetic Medical International Holdings Group Ltd..

4. FuboTV (FUBO) – 16.84%

NYSE ended the session with FuboTV rising 16.84% to $3.40 on Tuesday, after four consecutive sessions in a row of losses. NYSE dropped 0.05% to $15,050.82, after three successive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for FuboTV is 17330700 which is 29.19% above its average volume of 13414800.

FuboTV’s last close was $6.60, 89.4% under its 52-week high of $62.29.

FuboTV’s Sales

FuboTV’s sales growth is 134.7% for the current quarter and 68.6% for the next. The company’s growth estimates for the present quarter and the next is 61.8% and 73.4%, respectively.

FuboTV’s Revenue

Year-on-year quarterly revenue growth grew by 1541.1%, now sitting on 330.17M for the twelve trailing months.

FuboTV’s Stock Yearly Top and Bottom Value

FuboTV’s stock is valued at $3.40 at 17:32 EST, way under its 52-week low of $14.64.

FuboTV’s Moving Average

FuboTV’s worth is way below its 50-day moving average of $27.97 and way below its 200-day moving average of $26.76.

More news about FuboTV.

5. Cronos Group (CRON) – 14.52%

Cronos Group Inc. is a Cannabinoid Company in America and Internationally. The company manufactures and markets hemp-derived cosmetics and supplements through retail channels, ecommerce and other hospitality partners. It also cultivates, produces, and markets cannabis products and other cannabis-derived products. The company’s brands include PEACE NATURALS which is a global wellness platform. COVE and Spinach are adult-use brands. Hemp-derived CBD brands consist of Lord Jones as well as PEACE+. Cronos Group Inc. has its headquarters in Toronto, Canada.

NASDAQ ended the session with Cronos Group rising 14.52% to $3.24 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Volume

Today’s last reported volume for Cronos Group is 5434520 which is 149.37% above its average volume of 2179230.

Cronos Group’s last close was $2.83, 69.96% below its 52-week high of $9.42.

News about Cronos Group today

  • Cannabis company cronos group doubles revenue, beats analyst target. According to today’s article on MarketWatch, "Shares of Cronos Group are down 27.8% in 2022 compared to a drop of 40.9% by the Cannabis ETF . "

Cronos Group’s Revenue

Year-on-year quarterly revenue growth grew by 51.3%, now sitting on 74.44M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Cronos Group’s stock is considered to be overbought (>=80).

Cronos Group’s Stock Yearly Top and Bottom Value

Cronos Group’s stock is valued at $3.24 at 17:32 EST, way under its 52-week high of $9.42 and way above its 52-week low of $2.84.

Cronos Group’s Moving Average

Cronos Group’s worth is under its 50-day moving average of $3.45 and way below its 200-day moving average of $4.84.

More news about Cronos Group.

6. Avadel Pharmaceuticals plc (AVDL) – 11.45%

Avadel Pharmaceuticals plc is a US-based biopharmaceutical firm. The lead product candidate of the company is FT218, a sodium oxybate formulation. It is currently in a Phase 3-level clinical trial to treat excessive sleepiness and cataplexy among adults suffering from narcolepsy. Avadel Pharmaceuticals PLC was founded in January 2017 from Flamel Technologies SA. Avadel Pharmaceuticals plc is an Irish company that was founded in 2015. Its headquarters are in Dublin.

NASDAQ ended the session with Avadel Pharmaceuticals plc rising 11.45% to $4.38 on Tuesday while NASDAQ jumped 1.65% to $11,815.23.

Volume

Today’s last reported volume for Avadel Pharmaceuticals plc is 106744 which is 82.95% below its average volume of 626396.

Avadel Pharmaceuticals plc’s last close was $3.93, 66.09% under its 52-week high of $11.59.

The company’s growth estimates for the ongoing quarter and the next is a negative 39.4% and a negative 13.2%, respectively.

Avadel Pharmaceuticals plc’s Stock Yearly Top and Bottom Value

Avadel Pharmaceuticals plc’s stock is valued at $4.38 at 17:32 EST, way under its 52-week high of $11.59 and way above its 52-week low of $3.82.

Avadel Pharmaceuticals plc’s Moving Average

Avadel Pharmaceuticals plc’s value is way under its 50-day moving average of $6.54 and way under its 200-day moving average of $7.78.

More news about Avadel Pharmaceuticals plc.

7. argenx SE (ARGX) – 11.25%

Argenx SE is a biotech company in clinical stage. It focuses its efforts on antibody-based treatments for autoimmune diseases and cancer. The company is currently developing efgartigimod as a lead product candidate for patients suffering from myasthenia Gravis, immune thrombocytopenia, and pemphigus vulgaris. It also has Phase 2 clinical trials in the treatment of chronic inflammatory demyelinating neuropathy. ENHANZE SC are in preclinical stages. Cusatuzumab is being developed in the Phase 2 clinical stages in hematological carcinoma indications. Preclinical products include ARGX-117, which has therapeutic potential for both large autoimmune inflammatory and orphan diseases. ARGX-118 treats airway inflammation. ARGX-112 to treat skin inflammation, and ARGX115 for cancer immunotherapy are its partnered products. These are currently in Phase 1 clinical phases. ARGX116 is for treatment dyslipidemia, and ARGX114 is for treating fibrosis. AbbVie S.AEUR.R.L. is the company’s strategic partner. LEO Pharma A/S, Cilag GmbH International, Staten Biotechnology B.V. and Shire International GmbH. argenx SE was established in 2008, and it is located in Breda in the Netherlands.

NASDAQ ended the session with argenx SE rising 11.25% to $299.92 on Tuesday while NASDAQ rose 1.65% to $11,815.23.

Volume

Today’s last reported volume for argenx SE is 529779 which is 88.68% above its average volume of 280778.

argenx SE’s last close was $278.23, 22.02% under its 52-week high of $356.78.

argenx SE’s Sales

argenx SE’s sales growth is a negative 39.5% for the current quarter and a decline by 91% for the next. The company’s growth estimates for the current quarter and the next is a negative 12.8% and a negative 481.5%, respectively.

argenx SE’s Revenue

Year-on-year quarterly revenue growth declined by 46.5%, now sitting on 510.08M for the twelve trailing months.

argenx SE’s Stock Yearly Top and Bottom Value

argenx SE’s stock is valued at $299.92 at 17:32 EST, way below its 52-week high of $356.78 and way higher than its 52-week low of $248.21.

argenx SE’s Moving Average

argenx SE’s value is under its 50-day moving average of $303.38 and below its 200-day moving average of $304.77.

More news about argenx SE.

8. Berkeley Lights (BLI) – 10.56%

Berkeley Lights, Inc., is a digital cell biologist company that focuses on the acceleration and rapid development of cell-based biotherapeutics. It offers an integrated platform that includes proprietary consumables such as OptoSelect chips, reagent kit kits, automation systems and software for application and workflow. The company serves North America, Europe, Asia Pacific and Europe. Emeryville is the headquarters of this company, which was founded in 2011.

NASDAQ ended the session with Berkeley Lights jumping 10.56% to $4.92 on Tuesday while NASDAQ rose 1.65% to $11,815.23.

Volume

Today’s last reported volume for Berkeley Lights is 1107660 which is 9.89% below its average volume of 1229340.

Berkeley Lights’s last close was $4.45, 91.32% under its 52-week high of $51.28.

The company’s growth estimates for the current quarter is a negative 11.1% and positive 10% for the next.

Berkeley Lights’s Revenue

Year-on-year quarterly revenue growth grew by 6.6%, now sitting on 85.39M for the twelve trailing months.

Berkeley Lights’s Stock Yearly Top and Bottom Value

Berkeley Lights’s stock is valued at $4.92 at 17:32 EST, way below its 52-week high of $51.28 and way above its 52-week low of $4.01.

Berkeley Lights’s Moving Average

Berkeley Lights’s worth is way under its 50-day moving average of $6.21 and way under its 200-day moving average of $18.68.

More news about Berkeley Lights.

9. Viking Therapeutics (VKTX) – 10.27%

Viking Therapeutics, Inc. is a biopharmaceutical company at the clinical stage. It focuses its efforts on developing novel treatments for metabolic and endocrinological disorders. VK2809 is the company’s leading drug candidate. It is an oral tissue-subtype and receptor-subtype selective antagonist of the thyroid hormone receptor alpha. This is being tested in Phase 2b clinical trial to treat non-alcoholic steatohepatitis patients. VK5211 is the company’s leading drug candidate. This non-steroidal selective androgen-receptor modulator, which can be taken orally in Phase II clinical trial for patients with non-elective fracture surgery, is also available. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc., was established in 2012. It is located in San Diego, California.

NASDAQ ended the session with Viking Therapeutics rising 10.27% to $2.47 on Tuesday, after five successive sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Volume

Today’s last reported volume for Viking Therapeutics is 805844 which is 17.42% below its average volume of 975916.

Viking Therapeutics’s last close was $2.24, 77.8% under its 52-week high of $10.09.

The company’s growth estimates for the present quarter and the next is a negative 61.5% and a negative 46.7%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Viking Therapeutics’s stock is considered to be overbought (>=80).

Viking Therapeutics’s Stock Yearly Top and Bottom Value

Viking Therapeutics’s stock is valued at $2.47 at 17:32 EST, way under its 52-week low of $4.81.

Viking Therapeutics’s Moving Average

Viking Therapeutics’s worth is way under its 50-day moving average of $5.82 and way under its 200-day moving average of $6.03.

More news about Viking Therapeutics.

10. Seattle Genetics (SGEN) – 10.07%

Seattle Genetics, Inc. is a biotechnology firm that develops and markets therapies to treat cancer. ADCETRIS is an antibody-drug combination (ADC), for patients with Hodgkin lymphoma and CD30-positive T cell lymphomas. PADCEV is an ADC consisting of an anti-Nectin-4 monoclonal anti-tumor cells. It’s used to treat metastatic urothelial carcinomas. Tucatinib is an oral small-molecule TKI to HER2 that’s being studied; PADCEV, which is an ADC made of an anti-Nectin-4 monoclonal antibody, for the treatment of metastatic urothelial cancers. Tisotumab vedotin (ADC) is a human antibody, which binds with tissue factor and can be used to treat solid tumors such as cervical, ovarian and bladder. The company also develops ladiratuzumab vedotin which is an ADC for LIV-1, metastatic triple negative breast cancer, and SEA-BCMA. This antibody, which has been non-fucosylated BCMA directed, is clinically-staged, but not yet efficacious, to treat patients suffering from relapsed multiple myeloma. Seattle Genetics, Inc. is a partner in collaboration with Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, biotechnology, pharmaceutical, and Merck. Seattle Genetics, Inc. is an American company that was founded in 1997. Its headquarters are in Bothell, Washington.

NASDAQ ended the session with Seattle Genetics rising 10.07% to $119.77 on Tuesday while NASDAQ rose 1.65% to $11,815.23.

Volume

Today’s last reported volume for Seattle Genetics is 1534000 which is 51.41% above its average volume of 1013080.

Seattle Genetics’s last close was $108.81, 43.56% below its 52-week high of $192.79.

Seattle Genetics’s Sales

Seattle Genetics’s sales growth is a negative 32.3% for the current quarter and 39.7% for the next. The company’s growth estimates for the current quarter is a negative 191.1% and positive 32.8% for the next.

Seattle Genetics’s Revenue

Year-on-year quarterly revenue growth declined by 28.5%, now sitting on 1.57B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Seattle Genetics’s stock is considered to be overbought (>=80).

Seattle Genetics’s Stock Yearly Top and Bottom Value

Seattle Genetics’s stock is valued at $119.77 at 17:32 EST, way below its 52-week high of $192.79 and above its 52-week low of $117.46.

Seattle Genetics’s Moving Average

Seattle Genetics’s worth is way below its 50-day moving average of $139.00 and way under its 200-day moving average of $151.82.

More news about Seattle Genetics.

Most Active Losers Today

1. Alberton Acquisition Corporation (ALACW) – -55.56%

Alberton Acquisition Corporation has no significant operations. The company’s primary purpose is to enter into mergers, share-exchanges, asset acquisitions, stock purchases, recapitalizations, and other similar business combinations with target businesses. In July 2018, Alberton Acquisition Corporation was established. The former name of the company was Wisdom Resources Group Limited. Alberton Acquisition Corporation was established in 2005. It is located in Wan Chai in Hong Kong.

NASDAQ ended the session with Alberton Acquisition Corporation dropping 55.56% to $0.01 on Tuesday while NASDAQ jumped 1.65% to $11,815.23.

Alberton Acquisition Corporation’s last close was $0.01, 50% under its 52-week high of $0.02.

Alberton Acquisition Corporation’s Stock Yearly Top and Bottom Value

Alberton Acquisition Corporation’s stock is valued at $0.01 at 17:32 EST, way under its 52-week high of $0.02 and way above its 52-week low of $0.00.

More news about Alberton Acquisition Corporation.

2. Artelo Biosciences (ARTLW) – -28.81%

NASDAQ ended the session with Artelo Biosciences sliding 28.81% to $0.06 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three successive sessions in a row of losses, on what was an all-around up trend trading session today.

Artelo Biosciences’s last close was $0.06, 0% below its 52-week high of $0.06.

Artelo Biosciences’s Stock Yearly Top and Bottom Value

Artelo Biosciences’s stock is valued at $0.06 at 17:32 EST, below its 52-week low of $0.06.

More news about Artelo Biosciences.

3. Bellerophon Therapeutics (BLPH) – -24.14%

Bellerophon Therapeutics, Inc., is a company that develops products to treat cardiopulmonary disease in America. INOpulse is a proprietary platform that delivers pulsatile Nitric Oxide to treat pulmonary hypertension. INOpulse is currently in phase 2 of the clinical trial. It is being developed for treatment of pulmonary hypotension due to fibrotic interstitial pulmonary disease. Phase 2a of the clinical trial has been completed for pulmonary Hypertension as a result of chronic obstructive Pulmonary Disease. Phase 2a of the Phase 2a trial was conducted for patients with COVID-19. In January 2014, the company, formerly called Ikaria Development LLC, changed its name and became Bellerophon Therapeutics, Inc. Bellerophon Therapeutics, Inc. is located in Warren, New Jersey. It was established in 2009.

NASDAQ ended the session with Bellerophon Therapeutics dropping 24.14% to $0.90 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ jumped 1.65% to $11,815.23, after three sequential sessions in a row of losses, on what was an all-around up trend exchanging session today.

Volume

Today’s last reported volume for Bellerophon Therapeutics is 192516 which is 273.77% above its average volume of 51506.

Bellerophon Therapeutics’s last close was $0.90, 84.96% under its 52-week high of $5.95.

The company’s growth estimates for the current quarter is 25.6% and a drop 8.6% for the next.

Bellerophon Therapeutics’s Stock Yearly Top and Bottom Value

Bellerophon Therapeutics’s stock is valued at $0.90 at 17:32 EST, way below its 52-week high of $5.95 and higher than its 52-week low of $0.85.

Bellerophon Therapeutics’s Moving Average

Bellerophon Therapeutics’s worth is way under its 50-day moving average of $1.95 and way below its 200-day moving average of $3.01.

More news about Bellerophon Therapeutics.

4. American Virtual Cloud Technologies (AVCT) – -19.76%

American Virtual Cloud Technologies, Inc. offers managed IT services and IT solutions. It offers managed IT services to a range of clients, including unified communications-as-a-service, directory and messaging, enterprise networking, cybersecurity, collaboration, data center, integration, storage, backup, virtualization, and converged infrastructure. It was established in Atlanta, Georgia in 1987.

NASDAQ ended the session with American Virtual Cloud Technologies sliding 19.76% to $0.41 on Tuesday while NASDAQ jumped 1.65% to $11,815.23.

Volume

Today’s last reported volume for American Virtual Cloud Technologies is 2546840 which is 24.51% below its average volume of 3374040.

More news about American Virtual Cloud Technologies .

5. Adial Pharmaceuticals (ADILW) – -19.65%

NASDAQ ended the session with Adial Pharmaceuticals falling 19.65% to $0.32 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three consecutive sessions in a row of losses, on what was an all-around up trend trading session today.

Adial Pharmaceuticals’s last close was $0.32, 23.05% under its 52-week high of $0.42.

Adial Pharmaceuticals’s Stock Yearly Top and Bottom Value

Adial Pharmaceuticals’s stock is valued at $0.32 at 17:32 EST, below its 52-week low of $0.32.

More news about Adial Pharmaceuticals.

6. Axonics Modulation Technologies (AXNX) – -17.74%

Axonics, Inc., is a medical technology company that develops and sells sacral neuromodulation systems. Patients with an overactive bladder can use the company’s SNM system to manage their symptoms. These include urinary urge and frequency incontinence, as well as fecal and non-obstructive urine retention. The company’s rechargeable SNM System, (r-SNM), delivers gentle electrical pulses to the sacral nerve in order to normalize communication between the brain and bladder to help reduce symptoms such as bowel dysfunction and bladder problems. Bulkamid is a urethral bulking drug that can be used to relieve female stress-related urinary incontinence. The company sells products via a distributor network in the United States and abroad. In March 2021, the company, formerly Axonics Modulation Technology, Inc., changed its name and became Axonics Inc. Axonics Inc. was founded in 2012 in Irvine, California.

NASDAQ ended the session with Axonics Modulation Technologies dropping 17.74% to $39.50 on Tuesday while NASDAQ rose 1.65% to $11,815.23.

Volume

Today’s last reported volume for Axonics Modulation Technologies is 1629500 which is 225.46% above its average volume of 500663.

Axonics Modulation Technologies’s last close was $59.04, 26.02% below its 52-week high of $79.81.

Axonics Modulation Technologies’s Sales

Axonics Modulation Technologies’s sales growth is 43.5% for the ongoing quarter and 47% for the next. The company’s growth estimates for the ongoing quarter is a negative 27.6% and positive 35.1% for the next.

Axonics Modulation Technologies’s Revenue

Year-on-year quarterly revenue growth grew by 33.1%, now sitting on 161.94M for the twelve trailing months.

Axonics Modulation Technologies’s Stock Yearly Top and Bottom Value

Axonics Modulation Technologies’s stock is valued at $39.50 at 17:32 EST, way below its 52-week high of $79.81 and higher than its 52-week low of $38.41.

Axonics Modulation Technologies’s Moving Average

Axonics Modulation Technologies’s worth is way below its 50-day moving average of $58.19 and way below its 200-day moving average of $60.76.

More news about Axonics Modulation Technologies.

7. AlloVir (ALVR) – -17.51%

Allovir, Inc. is a company that specializes in cell therapy. It has a clinical stage and works to develop allogeneic, multi-virus-specific T cells (VSTs) therapies. These treatments are used to treat viral-related diseases. Viralym M, an allogeneic off-the shelf VST therapy that treats BK virus and cytomegalovirus as well as Epstein-Barr virus and human herpesvirus 6, is the company’s flagship product. ALVR106, a respiratory syncytial, parainfluenza, virus and influenza treatment, is the company’s lead product. ALVR109, COVID-19, SARS-CoV-2, COVID-19, ALVR107, ALVR107, ALVR107, and ALVR107 are preclinical development products. ALVR108 treats human herpesvirus-8. In May 2019, Allovir, Inc. was renamed from ViraCyte, Inc. Allovir, Inc. was established in 2013. It is located in Cambridge, Massachusetts.

NASDAQ ended the session with AlloVir falling 17.51% to $4.10 on Tuesday, following the last session’s downward trend. NASDAQ jumped 1.65% to $11,815.23, after three successive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Volume

Today’s last reported volume for AlloVir is 516254 which is 72.09% below its average volume of 1850350.

AlloVir’s last close was $4.10, 84.48% under its 52-week high of $26.41.

The company’s growth estimates for the ongoing quarter and the next is a negative 138.2% and a negative 50%, respectively.

AlloVir’s Stock Yearly Top and Bottom Value

AlloVir’s stock is valued at $4.10 at 17:32 EST, way under its 52-week high of $26.41 and above its 52-week low of $4.06.

AlloVir’s Moving Average

AlloVir’s worth is way below its 50-day moving average of $6.73 and way below its 200-day moving average of $14.89.

More news about AlloVir.

8. BELLUS Health (BLU) – -16.32%

BELLUS Health Inc. is a biopharmaceutical company in clinical stages that develops therapies for chronic cough and other hypersensitization conditions. BLU-5937 is the company’s leading drug candidate. It is an oral small molecule antagonist to P2X3 receptor. This Phase II clinical trial treats chronic cough and chronic pruritus. Laval is the company’s headquarters.

NASDAQ ended the session with BELLUS Health sliding 16.32% to $6.46 on Tuesday, after three sequential sessions in a row of losses. NASDAQ jumped 1.65% to $11,815.23, after three consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Volume

Today’s last reported volume for BELLUS Health is 1098800 which is 40.87% above its average volume of 779978.

BELLUS Health’s last close was $6.46, 34.35% below its 52-week high of $9.84.

BELLUS Health’s Revenue

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 16k for the twelve trailing months.

BELLUS Health’s Stock Yearly Top and Bottom Value

BELLUS Health’s stock is valued at $6.46 at 17:32 EST, way under its 52-week high of $9.84 and way higher than its 52-week low of $2.60.

BELLUS Health’s Moving Average

BELLUS Health’s value is way under its 50-day moving average of $7.24 and higher than its 200-day moving average of $6.16.

More news about BELLUS Health.

9. Arvinas (ARVN) – -15.63%

Arvinas, Inc. is a biopharmaceutical company in clinical stage. It focuses on the development, commercialization, and discovery of treatments to reduce disease-causing protein. ARV-110 is a PROTAC proteolysis-targeting chimera protein degrader. It’s currently in phase 1 clinical trials and targets the androgen receptor AR protein. ARV-471 is a PROTAC estrogen receptor protein. This treatment will be used to treat patients with metastatic ER+/HER2 positive breast cancer. Pfizer Inc., Genentech, Inc., Bayer AG, Insilico Medicine, Inc. and F. Hoffman-La Roche Ltd. have collaborated with the company. Arvinas, Inc., which was founded in 2013, is located in New Haven, Connecticut.

NASDAQ ended the session with Arvinas dropping 15.63% to $38.54 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.

Volume

Today’s last reported volume for Arvinas is 2134140 which is 326.43% above its average volume of 500456.

Arvinas’s last close was $38.54, 64.47% below its 52-week high of $108.47.

Arvinas’s Sales

Arvinas’s sales growth is 601.5% for the current quarter and 149.5% for the next. The company’s growth estimates for the present quarter and the next is 26.3% and 16.7%, respectively.

Arvinas’s Revenue

Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 22.59M for the twelve trailing months.

Arvinas’s Stock Yearly Top and Bottom Value

Arvinas’s stock is valued at $38.54 at 17:33 EST, way under its 52-week high of $108.47 and above its 52-week low of $37.41.

Arvinas’s Moving Average

Arvinas’s value is way below its 50-day moving average of $63.54 and way under its 200-day moving average of $77.09.

More news about Arvinas.

10. BridgeBio Pharma (BBIO) – -15.52%

BridgeBio Pharma, Inc. is involved in developing, delivering, and discovering medicines to treat genetic disorders. It has 30 product development programs, which include candidates for products ranging in stage from early discovery to advanced development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. It also develops products to treat genetic, dermatology, cancer, and other gene therapy disorders. BridgeBio Pharma, Inc. holds licenses and agreements with the Leland Stanton Junior University, The Regents of the University of California, Leidos Biomedical Research, Inc., the University of California, San Diego, Johns Hopkins University, University of Florida, University of Colorado Anschutz medical campus; Salk Institute for Biological Studies, Maze Therapeutics, UC San Francisco, the Canadian Glycomics Network, University of California, and Helsinn Group. This collaboration will allow for the evaluation of BBP-398. It was established in Palo Alto in California in 2015.

NASDAQ ended the session with BridgeBio Pharma falling 15.52% to $5.66 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ rose 1.65% to $11,815.23, after three sequential sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Volume

Today’s last reported volume for BridgeBio Pharma is 3470590 which is 38.57% above its average volume of 2504440.

BridgeBio Pharma’s last close was $5.66, 91.34% under its 52-week high of $65.33.

BridgeBio Pharma’s Sales

BridgeBio Pharma’s sales growth is 19367.2% for the ongoing quarter and a decline by 87.8% for the next. The company’s growth estimates for the current quarter and the next is 13.9% and 16.9%, respectively.

BridgeBio Pharma’s Revenue

Year-on-year quarterly revenue growth grew by 10462.3%, now sitting on 69.72M for the twelve trailing months.

BridgeBio Pharma’s Stock Yearly Top and Bottom Value

BridgeBio Pharma’s stock is valued at $5.66 at 17:33 EST, way under its 52-week high of $65.33 and higher than its 52-week low of $5.65.

BridgeBio Pharma’s Moving Average

BridgeBio Pharma’s value is way below its 50-day moving average of $9.59 and way under its 200-day moving average of $30.20.

More news about BridgeBio Pharma.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here